Showing results (71-80 of 122) with videos related to

Sort By:
Pageof 13
Pathology|March 18, 2023
Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphomaSiba El Hussein, L Jeffrey Medeiros, Kirill A Lyapichev, et al.
Blood|March 4, 2024
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitorWarren Fiskus, Jessica Piel, Mike Collins, et al.
Blood Cancer Journal|May 21, 2021
Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cellsWarren Fiskus, Christopher P Mill, Behnam Nabet, et al.
Blood|July 2, 2008
HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cellsRekha Rao, Warren Fiskus, Yonghua Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2005
Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2Purva Bali, Michael Pranpat, Ramona Swaby, et al.
Blood|October 30, 2004
Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3Prince George, Purva Bali, Srinivas Annavarapu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2007
Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90Warren Fiskus, Yuan Ren, Alex Mohapatra, et al.
The Journal of Biological Chemistry|June 7, 2005
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitorsPurva Bali, Michael Pranpat, James Bradner, et al.
The Journal of Biological Chemistry|March 7, 2009
p53 acetylation is crucial for its transcription-independent proapoptotic functionsHirohito Yamaguchi, Nicholas T Woods, Landon G Piluso, et al.
Cancer Research|May 20, 2004
Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3Prince George, Purva Bali, Pamela Cohen, et al.
Pageof 13